2026-01-14
HONG KONG, January 9, 2026 – Ribo LifeScience Co., Ltd. (“Ribo LifeScience” or the “Company,” Stock Code: 06938.HK), a leading company in small interfering RNA (siRNA) therapeutics and a multi-round investments portfolio company of Blue Ocean Capital Group (“BOCG”), has officially listed on the Main Board of the Hong Kong Stock Exchange. The Company successfully raised approximately HK$1.83 billion (after exercising the offer size adjustment option), marking the second-largest IPO in the 18A biotech sector since 2022 and the first IPO for Blue Ocean Capital in 2026.
Market Performance: A Strong Surge on Day One. Ribo LifeScience demonstrated exceptional market momentum on its first day of trading. The stock opened at HK$75 and closed at HK$82.1, achieving a final surge of 41.62%.
The global offering was led by CICC and Citigroup as joint sponsors. The Company issued 31,610,400 shares at a price of HK$57.97 per share. Public subscription in Hong Kong reached over 100 times, while the international offering was oversubscribed by 16.7 times, reflecting immense global investor confidence in the siRNA track. The IPO introduced 12 heavyweight cornerstone investors, including China AMC, Dacheng International, Dacheng Fund, and Taikang Life, who collectively subscribed to approximately 48.8% of the offering. Proceeds will be used to advance global multi-center clinical trials, support R&D pipelines, upgrade delivery platforms, and for general corporate purposes.
Blue Ocean Capital : A Long Term Strategic Partner. Throughout Ribo’s journey to IPO, Blue Ocean Capital has remained a dedicated partner through its three rounds investments. BOCG initially supported Ribo LifeScience through its RMB funds during the C1 and C+ rounds with investments totaling tens of millions of RMB, providing vital capital at critical clinical stages. To further support the Company’s international expansion and listing, BOCG reinvested several million dollars through its USD fund as an Anchor Investor during its IPO.
Technical Strength and Global Commercial Milestones. With 18 years of development, Ribo LifeScience has built a comprehensive R&D platform with independent intellectual property. Its innovative RiboGalSTAR™ liver-targeting delivery technology has successfully pushed multiple products into Phase II clinical trials. The Company operates R&D centers in Kunshan, Beijing, and Gothenburg (Sweden), forming an international R&D system with full-process global clinical development capabilities.Ribo has secured significant commercial collaborations, including a US$2 billion+ deal with Boehringer Ingelheim for MASH (fatty liver disease) and a deal exceeding RMB 700 million with Qilu Pharmaceutical for the Greater China rights of its cholesterol-lowering drug, RBD7022.
Dr. Liang Zicai, Co-founder, Chairman& CEO of Ribo LifeScience, commented:
“Listing on the Hong Kong Stock Exchange represents a major milestone in Ribo’s journey. We extend our sincere gratitude to global investors for their trust and support. Moving forward, we will leverage the international capital markets to accelerate the global clinical development and commercialization of siRNA therapeutics, further strengthen our technologies, deliver breakthrough therapies to patients worldwide while creating sustainable value for shareholders.”
Mr. Frank Yang, Founding Partner & CEO of BOCG, stated:
“Warmest congratulations to Ribo LifeScience on its successful listing! By utilizing the ‘China Discovery + Global Clinical’ model, Ribo can continue to compete alongside international giants in this ‘third wave of pharmaceuticals’ to develop life-saving drugs for patients worldwide. We will continue to support fort its global development in this new venture.”
About Ribo LifeScience (06938.HK) Ribo LifeScience is a global biopharmaceutical company listed in HKEX and focuses on the development and commercialization of siRNA therapies. Powered by its innovative technology platforms, the Company focuses on cardiovascular, metabolic, liver, and kidney diseases to provide revolutionary treatment solutions.
